Sai Life Sciences Q4 FY26: Profit ₹1025 Crore, Revenue ₹6101 Crore
Sai Life Sciences reported audited financial results for the quarter and year ended March 31, 2026. Q4 FY26 profit was ₹1,025.32 crore on revenue of ₹6,100.85 crore. Full-year FY26 profit was ₹3,414.81 crore on revenue of ₹22,023.57 crore.
The announcement of financial results, especially with strong growth figures, has a direct and significant impact on investor decisions and the company's stock performance.
The company reported significant year-on-year growth in both revenue and profit for the quarter and the full financial year, indicating strong financial performance.
Sai Life Sciences Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, following a Board of Directors meeting on May 14, 2026.
The company reported a profit after tax of ₹1,025.32 crore for the fourth quarter of FY26, a notable increase from ₹976.30 crore in the same quarter last year. Total income for the quarter stood at ₹6,100.85 crore, up from ₹5,576.26 crore in Q4 FY25.
For the full financial year ended March 31, 2026, the company posted a profit after tax of ₹3,414.81 crore, a significant jump from ₹1,734.62 crore in the previous fiscal year. Total income for FY26 reached ₹22,023.57 crore, compared to ₹16,793.83 crore in FY25.
The Board of Directors also noted the Auditors' Report from M/s. Deloitte Haskins & Sells LLP for the financial results.
What to do with a filing like this
Sai Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Life Sciences Limited. Read the original for the full detail.